Table 1.
Aims of RICORS2040.
| Specific aims: |
| 1. Improve kidney outcomes in men and women with diabetes or diabetic kidney disease (DKD) |
| Improve risk stratification in DKD to foster precision Nephrology |
| Evaluate novel strategies for kidney protection through therapeutic drug repositioning |
| Develop, evaluate and update Spanish Clinical Practice Guideline for detection and management of DKD. |
| 2. Improve kidney outcomes in men and women with primary glomerular disease |
| Improve risk stratification in glomerular disease to foster precision Nephrology |
| Evaluate novel kidney protective approaches in primary glomerular disease |
| Develop, evaluate and update clinical guidance documents |
| 3. Improve kidney outcomes in men and women with inherited kidney disease |
| Increase awareness of inherited kidney disease with special focus on glomerular and tubular kidney disease |
| Improve risk stratification in inherited glomerular disease to foster precision Nephrology |
| Identify genetic predictors of CKD progression |
| Develop, evaluate and update clinical guidance documents |
| 4. Define accelerated kidney aging as a cause of CKD and slow the loss of GFR in men and women |
| Develop a working definition of accelerated kidney aging |
| Develop tools to predict and assess rapid CKD progression |
| Test novel therapeutic approaches to kidney protection |
| Develop, evaluate and update clinical guidance documents |
| 5. Improve kidney allograft outcomes and improve the outcomes in men and women with a functioning kidney graft |
| Improve the outcome of chronic allograft nephropathy, decreasing graft loss |
| Limit the negative impact of immune suppressive therapies on comorbidities and life-threatening complications. |
| Develop, evaluate, and update clinical guidance documents for precision immunosuppression |
| 6. Improve the outcomes of men and women with CKD by targeting the accelerated biological aging which is a consequence of CKD |
| Develop novel risk stratification tools for cardiovascular disease and CKD-MBD to foster precision Nephrology |
| Improve the recognition and outcome of frailty |
| Evaluate the long-term safety and efficacy of SARS-CoV-2 vaccines in persons with advanced CKD |
| Develop, evaluate, and update clinical guidance documents on key consequences of CKD, such as cardiovascular disease, CKD-MBD, frailty and susceptibility to severe SARS-CoV-2 infection |
The general aim of RICORS2040 is to improve kidney and person outcomes in men and women with CKD or at high risk of CKD. The name derives from the aim to prove wrong the dire predictions regarding the global burden of CKD by 2040, that closely reflect those for Spain: The GBD collaboration predicts that CKD will become the 5th global cause of death by 2040.